Our data demonstrated that (a) the BET inhibitor JQ1 has an anti‐tumour effect in CLL; (b) the combinatorial treatment of venetoclax plus JQ1 highly improves the apoptotic effect of single treatments, both in cell lines and patient‐derived models; (c) CLL cell line MEC‐1 can easily develop resistance to venetoclax; (d) JQ1 is strongly efficacious as second‐line strategy, in the case of emergence of venetoclax‐resistant clones. This evidence concerns the gene DNER and neoplasm.